日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids.

聚合酶 Ѳ 抑制剂与已批准和正在研究的药物在患者来源的肿瘤多细胞类型 (mct) 球体中的组合

Teicher Beverly A, Dexheimer Thomas S, Chen Li, Silvers Thomas, Jones Eric M, Coussens Nathan P, Eder J Paul, Doroshow James H

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

确定BRAFV600野生型转移性黑色素瘤的治疗方案:一项基于SU2C/MRA基因组学的临床试验

LoRusso, Patricia M; Sekulic, Aleksandar; Sosman, Jeffrey A; Liang, Winnie S; Carpten, John; Craig, David W; Solit, David B; Bryce, Alan H; Kiefer, Jeffrey A; Aldrich, Jessica; Nasser, Sara; Halperin, Rebecca; Byron, Sara A; Pilat, Mary Jo; Boerner, Scott A; Durecki, Diane; Hendricks, William P D; Enriquez, Daniel; Izatt, Tyler; Keats, Jonathan; Legendre, Christophe; Markovic, Svetomir N; Weise, Amy; Naveed, Fatima; Schmidt, Jessica; Basu, Gargi D; Sekar, Shobana; Adkins, Jonathan; Tassone, Erica; Sivaprakasam, Karthigayini; Zismann, Victoria; Calvert, Valerie S; Petricoin, Emanuel F; Fecher, Leslie Anne; Lao, Christopher; Eder, J Paul; Vogelzang, Nicholas J; Perlmutter, Jane; Gorman, Mark; Manica, Barbara; Fox, Lisa; Schork, Nicholas; Zelterman, Daniel; DeVeaux, Michelle; Joseph, Richard W; Cowey, C Lance; Trent, Jeffrey M

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

一项Ib期剂量递增研究,旨在评估Cobimetinib和Duligotuzumab在既往接受过治疗的KRAS突变型局部晚期或转移性癌症患者中的安全性、耐受性和药代动力学。

Lieu, Christopher H; Hidalgo, Manuel; Berlin, Jordan D; Ko, Andrew H; Cervantes, Andres; LoRusso, Patricia; Gerber, David E; Eder, J Paul; Eckhardt, S Gail; Kapp, Amy V; Tsuhako, Amy; McCall, Bruce; Pirzkall, Andrea; Uyei, Anne; Tabernero, Josep